Showing results (1351-1360 of 1,373) with videos related to

Sort By:
Pageof 138
Physical Review Letters|September 10, 2011
Magnetically guided fast electrons in cylindrically compressed matterF Pérez, A Debayle, J Honrubia, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Blood|October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
The Lancet. Oncology|October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Blood|September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaAurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood|October 13, 2016
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaThomas Dejoie, Jill Corre, Helene Caillon, et al.
Blood|March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialPhilippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialXavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Pageof 138